0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Recombinant Proteins & Antibodies

SARS-CoV-2 Mutants

Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.

SARS-CoV-2 Related Kits

ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.

Targets of CAR-T Cell Therapy

50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.                  

Full-length Transmembrane Proteins

Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.

Targets for ADCs

A collection of targets for ADC development which are of high specificity and bioactivities and suitable for immunization, antibody screening, cell based assay, etc.

Immune Checkpoints

A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.

Cytokines

Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.

BsAb targets

CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.

Fc Receptors

Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.

MABSOL® Biotinylated Proteins

The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.

Enzymes

Series of target enzymes, including ATP related enzymes, protease, kinase, and tool enzymes, including Nuclease, IdeS, Endo S, etc.

Anti-idiotypic Antibodies

To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.

Newly Added Products

Mutants from SARS-CoV-2 Emerging Variants Omicron and more

ACROBiosystems are going full steam ahead on developing a collection of recombinant antigens for emergency SARS-CoV-2 variants. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.

Star Staining fluorescent-labeled products

Star Staining products are developed by a new-generation site-specific labeling technology with Star Standard quality. These products are uniquely designed for detecting and monitoring CAR-T cells in clinical trials.

News Center

Congratulations to ACROBiosystems being Listed on domestic Shenzhen Stock Exchange
2021/10/21
Congratulations to ACROBiosystems being Listed on domestic Shenzhen Stock Exchange
ACROBiosystems is pleased to announce that on October 18, 2021 Beijing local time, the company was listed onthe Shenzhen Stock Exchange.
Learn more
According to the mutations: Why is Omicron causing such concern?
2021/11/30
According to the mutations: Why is Omicron causing such concern?
On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron. Due to its highly divergent, researchers are now highly focused on the influence of rare mutations present in Omicron on current vaccines and therapeutic antibodies.
Learn more
Accelerated Progress: Spike Protein Mutations on B.1.617 Identified and Studied
2021/05/11
Accelerated Progress: Spike Protein Mutations on B.1.617 Identified and Studied
After the sharp rise in COVID-19 cases and deaths in India over recent weeks, at least 20 countries have imposed travel bans and restrictions to and from India. The world again stands at a crossroad of the viral evolution.
Learn more
2021 Antibody Engineering Therapeutics
2021/12/12 - 2021/12/16
2021 Antibody Engineering Therapeutics
Speaker: JAMES WELLS, PH.D. , ANDREW WARD, PH.D., AVIV REGEV, PH.D., And more.
Time: December 12 - 16, 2021
Learn more

This web search service is supported by Google Inc.

totop